First-Line Nivolumab Monotherapy Active in Advanced NSCLC
- First-line nivolumab had an acceptable safety profile in patients with advanced NSCLC.
- Treatment was associated with durable responses, including complete responses.
- This antibody attacks cells that have a programmed cell death 1 antibody (about 40%)PD-L1 to undergo programmed cell death- a stealth whisper to the right protein . This is one of the demonstration of Precision cancer medicine. This is just the beginning. Similar results are being seen in late stage patients whose tumor are positive for PD L 1. This is HUGE stuff folks. A stealth missile was the dream of one of the actions of these antibodies and we are seeing it also can work in melanoma if they PD -L1 protein
As part of the phase I CheckMate 012 study reported by Gettinger et al in the Journal of Clinical Oncology, nivolumab (Opdivo) monotherapy was found to be active as first-line treatment in advanced non–small cell lung cancer (NSCLC). The study is also examining first-line nivolumab plus platinum-based doublets in this setting.
A total of 52 patients with stage IIIB to IV disease were treated with nivolumab at 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Treatment after disease progression was permitted.
Treatment-related adverse events of any grade occurred in 71% of patients, with the most common being fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%). Grade 3 or 4 treatment-related adverse events occurred in 19% of patients, with grade 3 rash being the most common (2 patients, 4%).
Study treatment was discontinued due to an adverse event in 6 patients (12%), including grade 4 increased alanine transaminase and grade 3 increased aspartate transaminase (in 1 patient) and cardiac failure, hyperglycemia, increased lipase, diarrhea, and pneumonitis (all grade 3, 1 patient each).
Confirmed objective response occurred in 12 of 52 patients (23%), including an ongoing complete response in 4. Response occurred by first tumor assessment at 11 weeks in 9 of 12 responders (75%). At the time of analysis, 8 responses were ongoing at 5.3+ to 25.8+ months. Response was observed in 9 of 32 patients (28%) with any degree of tumor PD-L1 (programmed cell death protein 1) expression and in 2 of 14 patients (14%) with no PD-L1 expression.
Median progression-free survival was 3.6 months, and progression-free survival at 24 weeks was 41%. Median overall survival was 19.4 months, with 1-year and 18-month rates of 73% and 57%, respectively.
The investigators concluded: “First-line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC.”
The study was supported by Bristol-Myers Squibb.
Scott Gettinger, MD, of Yale Cancer Center, is the corresponding author of the Journal of Clinical